MR. ZHENGYONG LUO
![Picture](/uploads/8/1/4/8/8148469/911726_1.jpg)
Name: Mr. Zhengyong Luo
Diagnosis: Diabetes
D.O.B: 01 January 1948
Gender: Male
Country: China
HISTORY
Patient Zhengyong Luo was a 66-year-old male patient from China who was admitted to Puhua International Hospital for Type-2 Diabetes.
In 2001, Mr. Luo’s fasting blood sugar was found to be high during the routine body check, with a level of more than 8.9mmol/l. He had no obvious symptoms. He was treated with metformin to control his blood sugar. However, he did not take the medication regularly. In 2004, the oral medication was changed to NovoNorm and Acarbose. His monitored blood sugar was apparently controlled well, but his glycosylated hemoglobin was not acceptable: even when rosiglitazone, the glycosylated hemoglobin was still not optimal (glycosylated hemoglobin in June 2010 was 8.3). Mr. Luo decided to try stem cell treatment for his Type-2 Diabetes, hoping to improve his disease and his general condition.
(In addition to his type 2 diabetes, Mr. Luo also had fatty liver and hyperlipidemia for many years.)
Medical condition before Stem Cell Treatment (SCT) for Type-2 Diabetes
Before Stem Cell Treatment (SCT) for his diabetes, Patient Zhengyong Luo was generally well with his daily life, though he would feel fatigue. The main problem for him was the high glycosylated hemoglobin.
Stem Cell Treatment (SCT) for Type-2 Diabetes
Mesenchymal stem cell injections for diabetes via intravenous approach and interventional approach
Medical condition after Stem Cell Treatment (SCT) for Type-2 Diabetes
17 days after stem cell treatment for his Type-2 Diabetes, Patient Zhengyong Luo’s blood sugar was controlled at a stable level. His glycosylated hemoglobin was 8.1: lower than his prior condition (8.3). However, it takes months for this index to normalize.
Follow Up
On 11th December 2010, PIH received anemail written by Mr. Luo:
“I am sorry to reply you late, as I am busy these days.
Since I was discharged from your hospital after stem cell treatment on 8th July, I followed your recommendation to control my diet and exercise regularly. I had a review of all the tests on 20th October. Except for my fasting blood sugar which was a little above the normal range (6.16mmol/l), the other tests were exciting for me. My glycosylated hemoglobin has decreased from 8.3 at admission to 5.39 now. What’s more, my fatty liver is cured now, and my lipid test is normal, as well as other tests.
I am very thankful for your work in your hospital. I will stay in contact with you to see whether I need to reduce my oral diabetic medications. Thanks again.”
Patient Zhengyong Luo was a 66-year-old male patient from China who was admitted to Puhua International Hospital for Type-2 Diabetes.
In 2001, Mr. Luo’s fasting blood sugar was found to be high during the routine body check, with a level of more than 8.9mmol/l. He had no obvious symptoms. He was treated with metformin to control his blood sugar. However, he did not take the medication regularly. In 2004, the oral medication was changed to NovoNorm and Acarbose. His monitored blood sugar was apparently controlled well, but his glycosylated hemoglobin was not acceptable: even when rosiglitazone, the glycosylated hemoglobin was still not optimal (glycosylated hemoglobin in June 2010 was 8.3). Mr. Luo decided to try stem cell treatment for his Type-2 Diabetes, hoping to improve his disease and his general condition.
(In addition to his type 2 diabetes, Mr. Luo also had fatty liver and hyperlipidemia for many years.)
Medical condition before Stem Cell Treatment (SCT) for Type-2 Diabetes
Before Stem Cell Treatment (SCT) for his diabetes, Patient Zhengyong Luo was generally well with his daily life, though he would feel fatigue. The main problem for him was the high glycosylated hemoglobin.
Stem Cell Treatment (SCT) for Type-2 Diabetes
Mesenchymal stem cell injections for diabetes via intravenous approach and interventional approach
Medical condition after Stem Cell Treatment (SCT) for Type-2 Diabetes
17 days after stem cell treatment for his Type-2 Diabetes, Patient Zhengyong Luo’s blood sugar was controlled at a stable level. His glycosylated hemoglobin was 8.1: lower than his prior condition (8.3). However, it takes months for this index to normalize.
Follow Up
On 11th December 2010, PIH received anemail written by Mr. Luo:
“I am sorry to reply you late, as I am busy these days.
Since I was discharged from your hospital after stem cell treatment on 8th July, I followed your recommendation to control my diet and exercise regularly. I had a review of all the tests on 20th October. Except for my fasting blood sugar which was a little above the normal range (6.16mmol/l), the other tests were exciting for me. My glycosylated hemoglobin has decreased from 8.3 at admission to 5.39 now. What’s more, my fatty liver is cured now, and my lipid test is normal, as well as other tests.
I am very thankful for your work in your hospital. I will stay in contact with you to see whether I need to reduce my oral diabetic medications. Thanks again.”